The authors report a case of a 40-year-old man presenting with chronic pelvic pain due to pudendal nerve entrapment, successfully treated with our body-own analgesic palmitoylethanolamide (PEA, Normast). Their hypothesis of its mechanism of action in this ailment is:

PEA may induce relief of neuropathic pain through an action upon receptors located on the nociceptive pathway as well as a more direct action on mast cells via an ALIA (autocoid local injury antagonism) mechanism. ^[1]

They conclude stating that: the present case suggests that PEA could be a valuable pharmacological alternative to the most common drugs (anti-epileptics and antidepressants) used in the treatment of neuropathic pain. 

PEA is an endogenous mediator whose levels are increased following neuroinflammatory or neuropathic conditions in both animals and humans, possibly to exert a local anti-inflammatory and analgesic action.^{[review of the available pre-clinical data, and first human studies." style="font-family: Verdana, Arial, Helvetica, sans-serif; text-decoration: underline; color: #000066; font-weight: bold; font-size: 12px; line-height: 20px">2]}  

Normast is registered in the Netherlands and some other European countries as food for medical purposes under the tradename Normast. 

Many different painstates have been succesfully treated with Normast, without bouthersome side effects, drug interactions and no dose ajustments necessary for the elderly and renal patients.